Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Covidien plc | d8k.htm |
Exhibit 99.1
Covidien plc
Operating Income
(dollars in millions)
| Fiscal 2010 Quarters Ended | Fiscal 2009 Quarters Ended | |||||||||||||||||||||||||||||||
| September 24, 2010 |
June 25, 2010 |
March 26, 2010 |
December 25, 2009 |
September 25, 2009 |
June 26, 2009 |
March 27, 2009 |
December 26, 2008 |
|||||||||||||||||||||||||
| Medical Devices |
$ | 548 | $ | 512 | $ | 508 | $ | 529 | $ | 486 | $ | 481 | $ | 439 | $ | 443 | ||||||||||||||||
| Pharmaceuticals |
62 | 83 | 101 | 84 | 79 | 91 | 101 | 72 | ||||||||||||||||||||||||
| Medical Supplies |
46 | 70 | 71 | 67 | 55 | 68 | 59 | 43 | ||||||||||||||||||||||||
| Operating income of reportable segments |
656 | 665 | 680 | 680 | 620 | 640 | 599 | 558 | ||||||||||||||||||||||||
| Unallocated amounts: |
||||||||||||||||||||||||||||||||
| Corporate expenses |
(108 | ) | (96 | ) | (109 | ) | (106 | ) | (94 | ) | (105 | ) | (111 | ) | (82 | ) | ||||||||||||||||
| Restructuring charges |
(20 | ) | (25 | ) | (26 | ) | (5 | ) | (44 | ) | (5 | ) | (9 | ) | (3 | ) | ||||||||||||||||
| Legal and environmental charges, including shareholder settlements |
— | — | — | (33 | ) | (111 | ) | — | (183 | ) | (36 | ) | ||||||||||||||||||||
| Charges associated with acquisitions, divestitures and licensing arrangements |
(85 | ) | (5 | ) | — | — | (57 | ) | (89 | ) | (20 | ) | — | |||||||||||||||||||
| Impact of Oxy ER (1) |
— | — | — | — | — | — | 251 | 94 | ||||||||||||||||||||||||
| Consolidated Operating Income |
$ | 443 | $ | 539 | $ | 545 | $ | 536 | $ | 314 | $ | 441 | $ | 527 | $ | 531 | ||||||||||||||||
| (1) | Represents the sales and direct costs attributable to selling oxycodone hydrochloride extended-release tablets (Oxy ER). |